ENDRA Life Sciences to Present at H.C. Wainwright Virtual BioConnect 2021 Conference

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Chairman and CEO Francois Michelon will showcase the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which visualizes tissue at a fraction of the cost of MRI, aimed initially at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The presentation will be available on the company's website starting January 11 at 6:00 a.m. Eastern time and archived for 90 days.

ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that Chairman and CEO Francois Michelon will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed here and on the Investor Relations section of the ENDRA website beginning on January 11, 2021 at 6:00 a.m. Eastern time and will be archived for 90 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/623551/ENDRA-Life-Sciences-to-Present-at-HC-Wainwright-Virtual-BioConnect-2021-Conference

FAQ

What date will ENDRA present at the BioConnect 2021 Conference?

ENDRA Life Sciences will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021.

What is TAEUS technology by ENDRA?

TAEUS® is a technology developed by ENDRA designed to visualize tissue similarly to MRI but at 1/50th the cost.

What diseases does ENDRA's TAEUS target?

ENDRA's TAEUS technology initially targets Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH).

When will the presentation be available for viewing?

The presentation will be available on ENDRA's website starting January 11, 2021, at 6:00 a.m. Eastern time.

Where can I access ENDRA's presentation after the conference?

The presentation will be archived on ENDRA's Investor Relations section for 90 days after it goes live.